Biotechnology Industry Organization (BIO) on Friday applauded President Barack Obama's “Precision Medicine Initiative.”
The initiative, included in Obama's 2015 budget, looks to take an individual's unique lifestyle, environment, genes and microbiomes in order to give more effective treatment for diseases such as cancer and diabetes.
For example, if a patient is allergic to something they would be tested to determine exactly what their allergy is for instead of prescribing a generic allergy medication.
“Precision medicine holds great promise for many health care interventions to occur much earlier and with increased accuracy,” said Jim Greenwood, president and CEO of BIO. “We are pleased that the Precision Medicine initiative and the Chronic Disease Initiative longitudinal study proposed by BIO hold promise of working very well together.”
Greenwood said BIO is looking forward to working with the Obama administration and the National Institutes of Health to implement the initiative and help develop policies supporting the program.
“Together, we are embarking on a new era that will transform health care through the use of next-generation modern medicines and diagnostics that promise to save lives and reduce and eliminate suffering,” Greenwood said.
BIO is the largest trade association in the world, and represents biotechnology companies, centers and academic institutions across the county and in 30 other nations.